Methylene Blue — Informed Consent (Off‑label Mitochondrial/Cognitive Support)

INFORMED CONSENT FOR METHYLENE BLUE — OFF‑LABEL MITOCHONDRIAL/COGNITIVE SUPPORT

§1 PURPOSE, CONTEXT, AND SCOPE

§1.1 This document constitutes an informed consent agreement between the Patient identified herein (the "Patient") and the Prescribing Physician acting on behalf of the Clinic. It is intended to document that the Patient has received, understood, and accepted comprehensive information regarding the proposed off‑label use of methylene blue for mitochondrial and cognitive support.

§1.3 Health optimization context: The Patient understands that the Clinic operates as a proactive health optimization / longevity practice. The Clinic is not an emergency provider.

§1.4 This consent is governed by the laws of Denmark and the European Union, including but not limited to the Danish Health Act (Sundhedsloven) and Regulation (EU) 2016/679 (General Data Protection Regulation).

§1.5 By signing this document, the Patient confirms they have had adequate time to read, consider, and ask questions.

§3 MEDICATION, CLASS, AND DESCRIPTION

§3.1 Methylene blue (methylthioninium chloride) is a synthetic dye compound that has been used medically for over 100 years. It acts as an alternative electron carrier in mitochondrial respiration and has various pharmacological effects.

§3.3 Approved indications: Methylene blue has been used medically for:

  • Treatment of methemoglobinemia (its primary indication)
  • Surgical dye/tracer
  • Ifosfamide‑induced encephalopathy
  • Vasoplegic syndrome (intraoperative)

§3.4 Off‑label use in this Clinic: Methylene blue is being prescribed at low doses (typically 0.5–4 mg/kg/day or lower, often in the range of 15–60 mg/day) for off‑label purposes related to:

  • Mitochondrial support and cellular energy optimization
  • Cognitive enhancement / neuroprotection
  • Mood support
  • Longevity / anti‑aging (hypothetical)

§3.5 The Patient understands that these uses are off‑label and not EMA‑approved indications.

§4 REGULATORY STATUS AND OFF‑LABEL USE

§4.1 Methylene blue is an established pharmaceutical compound with a long history of medical use.

§4.2 Off‑label use: The Patient understands that prescribing methylene blue for "mitochondrial support," "cognitive enhancement," "neuroprotection," or "longevity" is off‑label and is not an EMA‑approved indication.

§4.3 Evidence supporting off‑label use is derived from:

  • Preclinical studies showing effects on mitochondrial function
  • Small clinical studies in Alzheimer's disease and mood disorders (with mixed results)
  • Mechanistic research on its role as an electron carrier
  • Long history of use with relatively known safety profile (at appropriate doses)

§4.4 The Patient has been informed that the intended use is off‑label.

§5 PROPOSED BENEFITS OF TREATMENT

§5.1 Based on preclinical research and limited clinical data, proposed benefits may include:

§5.1.1 Mitochondrial support: Methylene blue can act as an alternative electron carrier in the mitochondrial electron transport chain, potentially bypassing dysfunctional complexes and improving cellular energy production.

§5.1.2 Cognitive effects: Some studies suggest potential cognitive benefits, particularly in conditions associated with mitochondrial dysfunction. Small studies in Alzheimer's disease and mild cognitive impairment have shown mixed results.

§5.1.3 Neuroprotective properties: Preclinical research suggests potential neuroprotective effects through antioxidant mechanisms and mitochondrial stabilization.

§5.1.4 Mood effects: Methylene blue has historical use as a mood stabilizer and some research suggests antidepressant properties.

§5.2 No guarantee of benefit: The Patient acknowledges that:

  • Benefits for cognitive enhancement in healthy individuals are not established
  • Individual responses vary
  • Benefits are not guaranteed

§6 MATERIAL RISKS AND ADVERSE EFFECTS

§6.1 Methylene blue has a relatively well‑characterized safety profile at low doses, but risks exist:

§6.2 Common adverse effects:

  • Blue/green discoloration of urine (harmless, expected)
  • Blue/green discoloration of stool
  • Mild GI upset (nausea, diarrhea)
  • Headache
  • Dizziness
  • Blue discoloration of skin (particularly with higher doses or IV use)
  • Unusual taste in mouth

§6.3 Serious adverse effects and interactions:

§6.3.1 SEROTONIN SYNDROME (CRITICAL DRUG INTERACTION):

Methylene blue inhibits monoamine oxidase (MAO) at therapeutic doses. When combined with serotonergic medications, it can cause serotonin syndrome — a potentially life‑threatening condition.

CONTRAINDICATED COMBINATIONS include:

  • SSRIs (e.g., sertraline, fluoxetine, escitalopram, paroxetine, citalopram)
  • SNRIs (e.g., venlafaxine, duloxetine)
  • MAOIs
  • Tricyclic antidepressants
  • Buspirone
  • Tramadol
  • Meperidine
  • Triptans
  • St. John's wort
  • Other serotonergic drugs

The Patient MUST disclose all current medications, especially antidepressants.

§6.3.2 G6PD deficiency: Methylene blue can cause severe hemolysis (destruction of red blood cells) in patients with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency. This can be life‑threatening.

  • G6PD testing may be recommended before starting methylene blue
  • The Patient should disclose any known G6PD deficiency or family history
  • The Patient should disclose any history of hemolytic anemia or favism

§6.3.3 Methemoglobinemia paradox: At very high doses (>7 mg/kg), methylene blue can paradoxically cause methemoglobinemia rather than treat it.

§6.3.4 Photosensitivity: Methylene blue can increase sensitivity to sunlight. Sun protection is advised.

§6.3.5 Teeth staining: Oral use may cause temporary blue staining of teeth and oral mucosa.

§6.3.6 Allergic reactions: Rare allergic reactions can occur.

§7 CONTRAINDICATIONS

§7.1 Absolute contraindications:

  • Known G6PD deficiency
  • Concurrent use of serotonergic medications (SSRIs, SNRIs, MAOIs, etc.)
  • Known hypersensitivity to methylene blue

§7.2 Relative contraindications/precautions:

  • Renal impairment (methylene blue is renally excreted)
  • History of hemolytic anemia
  • Unknown G6PD status (testing recommended)

§7.3 The Patient confirms they have disclosed all relevant medical history.

§8 DRUG INTERACTIONS

§8.1 CRITICAL — Serotonergic drugs: As described above, methylene blue must NOT be combined with SSRIs, SNRIs, MAOIs, or other serotonergic medications due to risk of serotonin syndrome.

§8.2 Other interactions:

  • Drugs metabolized by CYP enzymes may be affected
  • Photosensitizing drugs (additive photosensitivity)

§8.3 The Patient agrees to inform the Clinic before starting any new medication.

§9 ADMINISTRATION AND DOSING

§9.1 Methylene blue is typically administered orally (capsules or solution).

§9.2 Dosing: Low doses are used for off‑label cognitive/mitochondrial purposes (often 0.5–1 mg/kg/day, or approximately 15–60 mg/day).

§9.3 The Patient should take methylene blue with food to reduce GI upset.

§9.4 Formulation: Pharmaceutical‑grade methylene blue should be used (not industrial dye).

§10 MONITORING

§10.1 Monitoring may include:

  • Clinical assessment of symptoms and tolerability
  • G6PD testing (if not previously done)
  • Complete blood count (to monitor for hemolysis, especially in those at risk)
  • Renal function (if prolonged use)

§11 ALTERNATIVE TREATMENTS

§11.1 Alternatives include:

  • Lifestyle interventions for cognitive health (exercise, sleep, diet)
  • Other supplements with mitochondrial/nootropic effects (CoQ10, NAD+ precursors, etc.)
  • No pharmacological intervention

§11.2 The Patient confirms that alternatives have been discussed.

§13 LIMITATION OF LIABILITY / NO GUARANTEE

§13.1 Benefits are not guaranteed.

§13.2 The Patient understands that off‑label use is based on limited evidence.

§13.3 Nothing in this consent excludes liability that cannot be excluded under applicable Danish law.

§14 WITHDRAWAL OF CONSENT

§14.1 The Patient may withdraw consent and discontinue use at any time.

§15 DATA PROTECTION

§15.1 The Patient's personal data will be processed in accordance with GDPR.

§16 ACKNOWLEDGMENTS AND DECLARATIONS

By consenting, the Patient confirms the following:

  • I have read this consent document in its entirety and understand its contents.
  • I understand that methylene blue is being used off‑label for mitochondrial/cognitive support.
  • I understand the expected side effect of blue/green urine (harmless).
  • CRITICAL: I understand that methylene blue MUST NOT be combined with SSRIs, SNRIs, MAOIs, or other serotonergic medications due to risk of serotonin syndrome.
  • I have disclosed all current medications, especially any antidepressants or psychiatric medications.
  • I understand the risk of hemolysis in G6PD deficiency and have disclosed any known deficiency or relevant history.
  • I understand the photosensitivity risk and agree to use sun protection.
  • I understand that benefits are not guaranteed.
  • I have disclosed all relevant medical history and current medications.
  • I understand I must seek emergency care for severe symptoms.
  • I have had the opportunity to ask questions.
  • I voluntarily consent to use the prescribed medication under the regimen agreed with my clinician.